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In the present study, the mechanism of action and molecular basis for the activity of the first class of selective inhibitors of the human
excitatory amino acid transporter subtype 1 (EAAT1) and its rodent ortholog GLAST are elucidated. The previously reported specificity
of UCPH-101 and UCPH-102 for EAAT1 over EAAT2 and EAAT3 is demonstrated to extend to the EAAT4 and EAAT5 subtypes as well.
Interestingly, brief exposure toUCPH-101 induces a long-lasting inactive stateofEAAT1,whereas the inhibitionexertedbyclosely related
analogs is substantially more reversible in nature. In agreement with this, the kinetic properties of UCPH-101 unblocking of the trans-
porter are considerably slower than those of UCPH-102. UCPH-101 exhibits noncompetitive inhibition of EAAT1, and its binding site in
GLAST has been delineated in an elaboratemutagenesis study. Substitutions of several residues in TM3, TM4c, and TM7a of GLAST have
detrimental effects on the inhibitory potency and/or efficacy of UCPH-101 while not affecting the pharmacological properties of (S)-
glutamate or the competitive EAAT inhibitor TBOA significantly. Hence, UCPH-101 is proposed to target a predominantly hydrophobic
crevice in the “trimerization domain” of the GLAST monomer, and the inhibitor is demonstrated to inhibit the uptake through the
monomer that it binds to exclusively and not to affect substrate translocation through the other monomers in the GLAST trimer. The
allostericmodeofUCPH-101 inhibitionunderlines the functional importance of the trimerizationdomainof theEAATanddemonstrates
the feasibility of modulating transporter function through ligand binding to regions distant from its “transport domain.”
Introduction
(S)-Glutamate (L-glutamate, Glu) is the major excitatory neu-
rotransmitter in the mammalian CNS, where it plays numerous
physiological functions. Glu is also a key mediator of the neurotox-
icity underlying stroke and ischemia, and glutamatergic dysfunction
constitutes a major component in several neurodegenerative disor-
ders (Corona et al., 2007; Johnson et al., 2009). Furthermore,
modulation of glutamatergic neurotransmission is a highly pur-
sued strategy in the search for new treatments of epilepsy, pain,
and psychiatric disorders (Yogeeswari et al., 2009; Field et al.,
2011; Gitto et al., 2012).
Glu mediates its effects through numerous receptors and is
taken up into neurons and glial cells by sodium-dependent high-
affinity Glu transporters (Danbolt, 2001). The five excitatory
amino acid transporters (EAATs) belong to the solute carrier 1
transporter family, and the human EAAT1-EAAT5 subtypes cor-
respond to the rodent orthologs GLAST, GLT-1, EAAC1,
EAAT4, and EAAT5, respectively (Bunch et al., 2009). The sub-
types are differentially expressed in the CNS and at the cellular
level and thus play different roles in glutamatergic neurotrans-
mission (Maragakis and Rothstein, 2004; Bunch et al., 2009).
The insights into EAAT structure–function aspects have in
recent years been greatly advanced from crystal structures of a
prokaryotic homolog of the transporters, the GltPh transporter
from Pyrococcus horikoshii (Yernool et al., 2004; Boudker et al.,
2007; Reyes et al., 2009; Verdon and Boudker, 2012). The EAAT
(and GltPh) exists as a trimeric complex in which each monomer
constitutes an independent functional unit (Gendreau et al.,
2004; Grewer et al., 2005; Koch and Larsson, 2005; Leary et al.,
2007). The monomer consists of eight primarily -helical trans-
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membrane regions (TM1-TM8) and two reentrant helical hair-
pin loops (HP1, HP2), and intracellular N- and C-termini. The
N-terminal TM1-TM6 segment is arranged as a distorted cylin-
der forming the outer surface of the complex to its surroundings
and with the two other monomers in the trimer. Although inter-
monomeric contacts in the trimer are mediated by TM2, TM4,
and TM5 exclusively, the entire TM1-TM6 segment has been
termed the “trimerization domain” (Reyes et al., 2009; Verdon
and Boudker, 2012). The C-terminal segment (HP1/TM7/HP2/
TM8) is folded into a compact core containedwithin this cylinder
and constitutes the “transport domain” of themonomer (Kanner
and Zomot, 2008; Boudker and Verdon, 2010; Jiang and Amara,
2011).
Investigations into the physiological functions of the respec-
tive EAATs have long been hampered by the lack of truly selective
pharmacological tools (Bunch et al., 2009). Recently, we have
discovered the first class of specific EAAT1 inhibitors (Jensen et
al., 2009), and UCPH-101 from this series has subsequently been
applied in several studies of EAATs in native tissues (Lane and
Lawen, 2012; Lee et al., 2012; Okabe et al., 2012; Salvatore et al.,
2012; Uwechue et al., 2012). Comprehensive structure–activity
relationship studies have identified several key pharmacophore
elements and in this way elucidated the structural determinants
for EAAT1 activity of this compound scaffold (Jensen et al., 2009;
Erichsen et al., 2010; Huynh et al., 2012a; b). In the present study,
we have elucidated the mechanism of action and molecular basis
for the EAAT1 activity of UCPH-101 and its analogs from the
perspective of the transporter.
Materials andMethods
Materials. Culture media, serum, antibiotics, and buffers for cell culture
were obtained from Invitrogen. Glu was purchased from Sigma, DL-
threo--benzyloxyaspartate (TBOA) from Tocris Bioscience Cookson,
[ 3H]-D-aspartate ([ 3H]-D-Asp) fromPerkinElmer, and the FLIPRMem-
brane Potential Blue (FMP) assay dye from
Molecular Devices. The UCPH-101, UCPH-
102, UCPH-100, 1, 2, and 3 analogs (Fig. 1)
were synthesized as previously described (Jen-
sen et al., 2009; Erichsen et al., 2010) (analog 1;
M.N. Erichsen, J. Hansen, B. Abrahamsen,
T.H.V. Huynh, C.S. Demmer, A.A. Jensen, and
L. Bunch, unpublished observations). Human
EAAT1 cDNA was a kind gift from Dr. S.G.
Amara (University of Pittsburgh School of
Medicine, Pittsburgh, Pennsylvania), and
Dr. T. Rauen (University of Osnabru¨ck,
Osnabru¨ck, Germany) kindly provided the rat
GLAST andGLT-1 cDNAs. The rat EAAT4 and
mouse EAAT5 cDNAs were generous gifts
from Dr. J. Rothstein (Johns Hopkins Univer-
sity, Baltimore, Maryland) and Dr. Cordeiro
(Christian-Albrechts-University, Kiel, Ger-
many), respectively. The 5-HT3A and 5-HT3B
cDNAs were kind gifts from Drs. J. Egebjerg
and E.F. Kirkness, respectively, and the con-
struction of the HA-5-HT3B-pCIneo plasmid
has been described previously (Krzywkowski et
al., 2008).
Molecular biology. For the electrophysiolog-
ical recordings, human EAAT1, rat EAAT4,
and mouse EAAT5 were expressed in tsA201
cells as fusion proteins containing an amino-
terminal fluorescent protein. The construct en-
coding EAAT1 was formed by linking the
coding region of EAAT1 via an AgeI site with a
yellow fluorescent protein (YFP) into an open
reading frame and subcloning into
pcDNA3.1() was performed by using EcoRI and XbaI restriction sites.
Comparable expression constructs were generated for rat EAAT4 and
mouse EAAT5, which were linked via BsrGI to a monomeric YFP
(mYFP). The BsrGI site was created by introduction of a silent mutation
with PCR. The rEAAT4 cDNA was subcloned into pcDNA3.1() using
BamHI and BsgI, and mEAAT5 cDNA into pcDNA3.1() using BspEI
and HindIII restriction sites.
The rat GLAST and GLT-1 cDNAs were subcloned from their original
vectors into pcDNA3.1/hygro using the restriction enzymes NheI and
XhoI. Chimeric GLAST/GLT1 constructs were constructed by use of
splicing overlap extension PCR (Horton et al., 1989). This method was
also used to insert a DNA sequence encoding for the HA epitope into
GLAST-pcDNA3.1/hygro and EAAT1-pcDNA3. Mutations were in-
troduced into the GLAST- and GLT1-pcDNA3.1/hygro plasmids by
the QuikChange mutagenesis kit (Stratagene). The absence of unwanted
mutations in all cDNAs created by PCRwas verified by DNA sequencing
(Eurofins MWG Operon).
Cell culture and transfections. HEK293, tsA201, and stable EAAT1-
HEK293 cells (Jensen and Bra¨uner-Osborne, 2004) were cultured in
GlutaMAX-I DMEM supplemented with penicillin (100 U/ml), strepto-
mycin (100 g/ml), and 5% dialyzed FBS (the medium for the EAAT1-
HEK293 cell linewas supplementedwith 1mg/mlG-418) in a humidified
atmosphere of 5% CO2 at 37°C. For the transfection of tsA201 cells, 8
105 cells were split into a 6 cm tissue culture plate and transfected the
following day with a total of 4 g cDNA using Polyfect according to
the manufacturer’s instructions (QIAGEN), and the cells were used for
the various assays 40–48 h after the transfection. Analogously to the
procedure used in a previous study (Jensen et al., 2007), polyclonal
HEK293 cell lines stably expressing wild-type (WT) GLAST,WTGLT-1,
chimeric GLAST/GLT-1 transporters, and GLAST and GLT-1 mutants
were generated by culturing the transfected cells in medium containing
300g/ml hygromycin B for 3–4 weeks before use. The tsA201 cells used
for the electrophysiological recordings were transfected using the
Ca3(PO4)2 technique as previously described (Melzer et al., 2003). In
these recordings, two independent recombinants were tested and shown
to exhibit indistinguishable functional properties.
Figure 1. Chemical structures of UCPH-101 and the five additional analogs used in this study. The parental chromene skeleton
with its R1 and R2 substituents is given for reference.
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Electrophysiological recordings. Standard whole-cell patch-clamp re-
cordings were performed using an Axopatch 200B amplifier (Molecular
Devices) as described previously (Melzer et al., 2003;Winter et al., 2012).
Borosilicate pipettes were pulled with resistances between 1.0 and 2.0
M. Cells were clamped to 0 mV for 1 s or 2 s between test sweeps.
Voltage errors were reduced by compensating at least 80% of series re-
sistance by an analog procedure. Cells with current amplitudes10 nA
were excluded from the analysis. Currents were low-pass filtered at 5 kHz
and digitized with a sampling rate of 20 kHz using a Digidata AD/DA
converter (Molecular Devices).
Bath solutions contained (in mM) 140 NaNO3, 4 KCl, 2 CaCl2, 1
MgCl2, 20 HEPES, 5 tetraethylammonium chloride, and 0.5 or 1 Glu,
respectively. Pipettes were filled with 115 KNO3, 2 MgCl2, 5 EGTA, and
10 HEPES. Glu- and UCPH-101-dependences were determined by ap-
plication of indicated concentrations of Glu or/and the inhibitor. In bath
or internal solutions, pH was adjusted to 7.4 with NaOH or KOH, re-
spectively. External and internal salt agar bridges were made from a
plastic tube filled with 140 mM KCl in 3% agar and used for electrical
connection with the Ag/AgCl electrode.
[3H]-D-Asp uptake assay.The [3H]-D-Asp uptake assay was performed
essentially as previously described (Jensen and Bra¨uner-Osborne, 2004).
Briefly, cells were split into poly-D-lysine-coated white 96-well plates
(PerkinElmer). At 16–24 h later, the culture medium was aspirated, and
cells were washed once with 100 l assay buffer (HBSS supplemented
with 20 mM HEPES, 1 mM CaCl2, and 1 mM MgCl2, pH 7.4). Then 50 l
assay buffer supplemented with 100 nM [3H]-D-Asp and various concen-
trations of test compound were added to the wells, and the plate was
incubated at 37°C for 6 min. Nonspecific [ 3H]-D-Asp uptake was deter-
mined in wells with 3 mM Glu. The assay mixtures was quickly removed
from the wells, which were then washed with 2  100 l ice-cold assay
buffer, and 150 l Microscint20 scintillation fluid (PerkinElmer) was
added to each well. The plate was shaken for 1 h and counted in aWallac
1450 MicroBeta Trilux scintillation counter (GMI). The experiments
were performed in duplicate at least 3 times for each ligand at the various
transporters. Specific details concerning the experiments where preincu-
bation and washing steps were performed before the execution of the
[ 3H]-D-Asp uptake are given in the legend to Figure 3.
FMP assay. The functional characterization of UCPH-101 and TBOA
at stable EAAT1-HEK293 cells in the FMP assay was performed essen-
tially as previously described (Jensen and Bra¨uner-Osborne, 2004). Cells
were split into poly-D-lysine-coated black 96-well plates with clear bot-
tom (BD Biosciences). At 16–24 h later, the medium was aspirated, and
the cells were washed with 100 l Krebs buffer [140 mM NaCl/4.7 mM
KCl/2.5 mM CaCl2/1.2 mM MgCl2/11 mM HEPES/10 mM D -glucose, pH
7.4]; 50 l Krebs buffer supplemented with various concentrations of
UCPH-101 or TBOAwas added to the wells, after which an additional 50
l Krebs buffer supplemented with the FMP assay dye (1 mg/ml) was
added to each well. The plate was incubated at 37°C in a humidified 5%
CO2 incubator for 30min and assayed in aNOVOstar plate reader (BMG
Laboratory Technologies) measuring emission [in fluorescence units
(FU)] at 560 nm caused by excitation at 530 nm before and up to 1 min
after addition of 33l Glu solution. The experiments were performed in
duplicate at least three times for each compound.
Quantification of transporter expression by ELISA. The ELISA was per-
formed essentially as previously described (Krzywkowski et al., 2008).
Briefly, tsA201 cells were transfected with EAAT1-pcDNA3, GLAST-
pcDNA3.1/hygro, HA-EAAT1-pcDNA3, or HA-GLAST1-pcDNA3.1/
hygro, or cotransfected with 5-HT3A-pCIneo and HA-5-HT3B-pCIneo
(ratio 1:1). At 16–24 h after the transfection, the cells were plated into
poly-D-lysine-coated 48-well plates (1.5 105 cells/well). The following
day, the cells were washed in ice-cold assay buffer (PBS supplemented
with 1 mM CaCl2), after which the cells were fixed by treatment of 4%
paraformaldehyde (in PBS) on ice. The remaining steps were performed
at room temperature. The cells were washed three times in assay buffer
and incubated with blocking solution (3%drymilk in 50mMTris-HCl, 1
mM CaCl2, pH 7.5) for 20 min. After blocking, the cells were incubated
with mouse anti-HA antibody (Nordic Biosite, diluted 1:1000 in block-
ing solution) for 45 min. The cells were then washed three times with
assay buffer and incubated with blocking solution for 20 min before
incubation with horseradish peroxidase-conjugated secondary antibody
(Invitrogen, diluted 1:400 in blocking solution) for 45 min. After three
washes with assay buffer, the subunit expression was quantified using
the 3,3,5,5-tetramethylbenzidine liquid substrate system (Sigma). The
reaction was quenched with 1NH2SO4 after which the absorbance of the
supernatants was determined at 450 nm. Total expression levels were
determined by adding 0.1% Triton X-100 to the blocking solution used
for the first blocking incubation and the incubation with anti-HA anti-
body. All ELISA experiments were performed in quadruplicate. Specific
details concerning the preincubation and washing steps performed be-
fore the execution of the ELISA in the determination of the effects of
UCPH-101 preincubation on transporter expression levels are given in
the legend for Figure 3F.
Data analysis. Data from the electrophysiological recordings were an-
alyzedwith a combination of pClamp10 (MolecularDevices) and Sigma-
Plot11 (Jandel Scientific) programs. Current amplitudes were used
without any subtraction procedure. Data are given as mean  SE. In
experiments where UCPH-101 or UCPH-102 concentration depen-
dences were determined, we obtained relative errors for apparent disso-
ciation constants as SEs of fit estimates from fitting a Hill equation to the
concentration dependence of EAAT1 anion currents. To evaluate time-
constants for UCPH-binding and -unbinding events on EAAT1 trans-
porters, we fitted monoexponential functions to the time courses of
changes in EAAT1 mediated anion currents.
Concentration-inhibition curves for Glu and the inhibitors at the
transporters in the [ 3H]-D-Asp uptake assay were constructed based on
the radioactivity level (CPM) measured in the respective wells, after the
nonspecific uptake measured in the presence of 3 mM Glu had been
subtracted. Concentration–response curves for Glu and concentration–
inhibition curves for UCPH-101 and TBOA at EAAT1-HEK293 cells in
the FMP assay were constructed based on the difference in the fluores-
cence (FU) between the maximal fluorescence recorded before and
after addition of Glu obtained for the different ligand concentrations. All
curves were generated by nonweighted least-squares fits using the pro-
gram KaleidaGraph 3.6 (Synergy Software). As for the ELISA, the basal
absorbance measured in wells containing tsA201 cells transfected with
(untagged) WT EAAT1 or WT GLAST were subtracted from the absor-
bance measured from cells transfected with HA-EAAT1 cDNA or with
cDNAs encoding for HA-GLAST and various HA-GLAST mutants, re-
spectively.
Computational chemistry. The in silico studies were performed using
the comprehensive software suite MOE (Version 2012.05, Chemical
Computing Group) installed on a PC-Windows 7 professional, 32-bit
platform.Homologymodeling: A homologymodel of ratGLASTwas built
based on an aligment of its amino acid sequence (NP_062098) with that
of the GltPh transporter. The residues Phe
190-Val 241 segment (both res-
idues included) between TM4b and TM4c in GLAST is absent in GltPh
(Yernool et al., 2004), and analogously to a previously published homol-
ogymodel of EAAT1 this segment was deleted from theGLAST sequence
before construction of the homology model (Huang and Vandenberg,
2007). The homology model of GLAST was built from the 3D coordi-
nates of the crystal structure of GltPh in complex with L-aspartate and
Na [PDB code 2NWX (Boudker et al., 2007)] using standard setup
parameters. Binding site: Exploration of the binding site was done using
the build-in function “Site Finder” (standard setup).
The logP and total polar surface area (tPSA) values for UCPH-101,
UCPH-102, UCPH-100, 1, 2, and 3 were calculated using the standard
parameters in the setup box.
Results
UCPH-101 and UCPH-102 are highly selective inhibitors of
EAAT1 over other EAATs
UCPH-101 and UCPH-102 have previously been shown to be
specific inhibitors of human EAAT1 and its rat ortholog GLAST
displaying high nanomolar IC50 values at these transporters and
negligible inhibitory activity at human EAAT2, human EAAT3,
rat GLT-1, and rat EAAC1 at concentrations up to 100 M
(Jensen et al., 2009; Erichsen et al., 2010). To investigate whether
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this selectivity extends to the entire EAAT family, the functional
properties of UCPH-101 and UCPH-102 were characterized by
patch-clamp electrophysiology on tsA201 cells expressing human
EAAT1, rat EAAT4, and mouse EAAT5 (Fig. 2).
EAAT anion currents were measured with internal KNO3 and
NaNO3-based external solution at a saturating Glu concentra-
tion. The use of NO3
 increases anion currents and permits mea-
surements of anion currents in isolation. Representative current
recordings of EAAT1, EAAT4, and EAAT5 from individual cells
before and after application of saturating concentrations of
UCPH-101 are given in Figure 2A, C, and E, respectively. Cur-
rent–voltage relationships for EAAT1 (Fig. 2B), EAAT4 (Fig. 2D),
and EAAT5 (Fig. 2F) in the absence (gray circles) and presence of
10 M UCPH-101 (black circles) illustrate the effects of the in-
hibitor on the different EAAT-isoforms.
UCPH-101 and UCPH-102 inhibited EAAT1 anion currents
in a concentration-dependent manner, with KD values of 0.34
0.03M(Hill	 1.3 0.13,n 9) forUCPH-101 and 0.17 0.02
M (Hill 	 0.97  0.11, n  7) for UCPH-102 (Fig. 2G). At
saturating UCPH-101 or UCPH-102 concentrations, EAAT1
currents were not different from anion currents in untransfected
cells (Fig. 2B, E), indicating complete block of EAAT1 by both
compounds. Thus, the block of EAAT1 exerted by UCPH-101
and UCPH-102 can be described accurately by whole-cell
recordings.
In contrast to their observed activity at EAAT1, neither
UCPH-101 nor UCPH-102 caused significant inhibition of
whole-cell currents in EAAT4-expressing (Fig. 2D,H) or
EAAT5-expressing cells (Fig. 2F,H) at final concentrations of 10
M. We conclude that neither EAAT4 nor EAAT5 is blocked by
UCPH-101 or UCPH-102 in the low concentration range de-
tected for EAAT1; thus, these data further support the notion of
these compounds being highly selective inhibitors of EAAT1.
UCPH-101 induces long-lasting inhibition of EAAT1
In preliminary studies of various assay parameters in the [3H]-D-
Asp uptake assay, the duration of the incubation time was found
to be important for the activity of UCPH-101 at EAAT1. A sig-
nificant, albeit modest, increase in the inhibitory potency of
UCPH-101 at the transporter was observed with increasing du-
rations of the incubation period, whereas the IC50 values for Glu
and TBOA did not change significantly (Fig. 3A). Strikingly, pre-
incubation of EAAT1-HEK293 cells with UCPH-101 followed by
extensive washing resulted in a dramatic reduction in the specific
[3H]-D-Asp uptake mediated by the cells (Fig. 3B). In contrast,
preexposure of the cells to TBOA in concentrations up to 100-
fold higher than its IC50 value followed by the same washing
regimen did not impair transporter function significantly (Fig.
3B). The impact of UCPH-101 preincubation on EAAT1 func-
tion was concentration-dependent, and the degree of inhibition
observed after preincubation was not altered significantly with
different washing regimens (Fig. 3B). Even brief preincubation
(
6 s) with 100 M UCPH-101 induced long-lasting inhibition
of EAAT1, although the potency of the compound in its induc-
tion of this long-lasting inhibition increased with longer prein-
cubation periods (Fig. 3C). Incubation of the EAAT1-HEK293
cells with 3 mM Glu or 300 M TBOA before and concomitant
presence of 3 mM Glu or 300 M TBOA during the UCPH-101
preincubation did not alleviate the impairment of EAAT1 func-
tion brought on by UCPH-101 (Fig. 3D), nor did an incubation
with 3 mM Glu or 300 M TBOA in between the UCPH-101
preincubation and the execution of the [3H]-D-Asp uptake assay
(Fig. 3E).
Figure2. EffectsofUCPH-101andUCPH-102onwhole-cell currentsofEAAT1,EAAT4,andEAAT5.
A, C, E, Representative whole-cell currents from tsA201 cells expressing EAAT1 (A), EAAT4 (C), and
EAAT5(E) intheabsence(top)andpresence(bottom)of10MUCPH-101.Thecompoundwasadded
tobathsolutioncontaining140mMNaNO3and0.5mMGlu,andcellsweredialyzedwith115mMKNO3.
Dotted lines represent0nA.B,D,F, Current–voltage relationshipofEAAT1(n	14) (B), EAAT4(n	
16) (D), and EAAT5 (n	 11) (F ) in the absence ( ) or presence (F) of 10MUCPH-101. Untrans-
fected tsA201 cells perfused with external solution containing 0.5mM Glu were used as control (E)
(n	 9). G, Application of different concentrations of UCPH-101 or UCPH-102 to cells expressing
EAAT1 at a voltage step of185mV (solutions as in A–F ). Data were normalized to the current in
absence of compounds. Fitting concentration dependences of EAAT1 steady-state currents (arrow in
Fig. 2A) with a Hill equation provided dissociation constants of 0.34 0.03M (Hill coefficient	
1.3 0.13, n 9) for UCPH-101 and 0.17 0.02M (Hill coefficient	 0.97 0.11, n 7) for
UCPH-102.H, Effect of10MUCPH-101or10MUCPH-102onanioncurrentsof EAAT1, EAAT4, and
EAAT5 at a voltage step of185 mV (solutions as in A–F ). To determine the inhibitory effect of
UCPH-101(blackbar)andUCPH-102(graybar)onEAAT-mediatedanioncurrents,wedividedsteady-
statecurrents in thepresenceofUCPH-101/UCPH-102bycurrents in theabsenceof compounds.Data
are given asmean SE.
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Figure 3. UCPH-101 induces a long-lasting inactive state of EAAT1. A, The inhibitory potency of UCPH-101 at EAAT1-HEK293 cells increases with the length of the incubation period in the
[ 3H]-D-Asp uptake assay, whereas those of Glu and TBOA do not. The IC50 (pIC50 SEM) values of UCPH-101 using incubation periods of 1.5, 3, 6, and 12 min were 1.9M (5.71 0.05), 1.1M
(5.97 0.07), 0.82M (6.09 0.05), and 0.44M (6.36 0.04), respectively (n	 4). B, Preincubation of EAAT1 with UCPH-101 induces long-lasting inhibition of (Figure legend continues.)
1072 • J. Neurosci., January 16, 2013 • 33(3):1068–1087 Abrahamsen et al. •Mechanism of Action of the EAAT1-Inhibitor UCPH-101
Exposure of EAAT1 and GLAST to UCPH-101 does not
internalize the transporters
Sustained exposure of the serotonin transporter (from the SLC6
transporter family) to inhibitors has been reported to internalize
the transporter in mammalian cell lines and neurons (Lau et al.,
2008; Kittler et al., 2010), and antagonist-induced internalization
has also been demonstrated for several membrane-bound recep-
tors (Roettger et al., 1997; Gray and Roth, 2001; Pheng et al.,
2003; Rojas et al., 2010). To investigate whether the observed
long-lasting effects of UCPH-101 preincubation on EAAT1 func-
tion could arise from an analogous ligand-induced internaliza-
tion of the transporter, the effects of UCPH-101 on the
expression levels of EAAT1 and GLAST at the cell surface were
investigated in an ELISA using HA-tagged transporters tran-
siently expressed in tsA201 cells. The validity of this assay was
verified in control experiments performed in parallel, where ex-
pression of an HA-tagged 5-HT3B receptor subunit in tsA201
was found not to result in significant cell surface expression,
whereas of coexpression ofHA-5-HT3Bwith 5-HT3Agave rise to
the significant levels of cell surface expression of the tagged sub-
unit (B. Abrahamsen andA.A. Jensen, unpublished observations)
(Krzywkowski et al., 2008).
The HA epitope (YPYDVPDYA) was inserted between resi-
dues Pro179 and Pro180 in both EAAT1 andGLAST. In a previous
study, mouse GLT-1 tagged with HA in the corresponding posi-
tion has been shown to exhibit pharmacological properties not
significantly different from those of the WT transporter (Peacey
et al., 2009). Analogously, the IC50 values displayed by Glu,
TBOA, and UCPH-101 at HA-EAAT1 and HA-GLAST in the
[3H]-D-Asp uptake assay were not significantly different from
those displayed by the ligands at the two WT transporters (B.
Abrahamsen and A.A. Jensen, unpublished observations). As can
be seen from Figure 3F, preincubation of tsA201 cells transiently
expressing HA-EAAT1 and HA-GLAST with 100MUCPH-101
did not result in significant reduction in the numbers of cell
surface-expressed transporters compared with control cells. A
small but significant decrease in the total expression levels of both
HA-EAAT1 and HA-GLAST was observed in cells preincubated
with 100 M UCPH-101 (p	 0.048 and p	 0.049, respectively;
Fig. 3F). However, these differences are not considered pertinent
from a biological perspective.
UCPH-101 and closely related analogs induce substantially
different time-dependent inhibition of EAAT1
To shed light on the structural elements in the UCPH-101 mol-
ecule important for its long-lasting impairment of EAAT1-
mediated uptake, the effects of preincubation of EAAT1 with five
closely related UCPH-101 analogs on transporter function were
investigated. The five analogs have the parental chromene skele-
ton in common with UCPH-101, but their 4- and 7-substituents
differ (Fig. 1). Interestingly, the pronounced impairment of
EAAT1uptake observed after preincubationwithUCPH-101was
contrasted by much more moderate effects on transporter func-
tion resulting from preexposure to the five analogs (Fig. 3G;
Table 1). UCPH-101, UCPH-102, and 1 display similar inhibi-
tory potencies at EAAT1 in the [3H]-D-Asp assay (Table 1) and,
in the case of UCPH-101 and UCPH-102, in the electrophysio-
logical recordings (Fig. 2). Nevertheless, UCPH-101was found to
be
100-foldmore potent than both analogs when it came to the
induction of the inactive EAAT1 state in the preincubation ex-
periments (Fig. 3G; Table 1). Preincubation of EAAT1 with the
UCPH-100, 2, and 3 analogs had moderate or negligible effects
on transporter function (Fig. 3G; Table 1). The divergence of
UCPH-101 from the other analogs is illustrated by the fact that
the correlation between the inhibitory potencies for UCPH-102,
4
(Figure legend continued.) transporter function. EAAT1-HEK293 cells were incubated with
buffer or buffer supplementedwith various concentrations of UCPH-101 or TBOA for 15min and
washed for 3 15, 3 30, or 3 45min before determination of specific [ 3H]-D-Asp uptake
(n	 4). C, The degree of EAAT1 inhibition induced by preincubation with UCPH-101 increases
with the duration of the preincubation. EAAT1-HEK293 cellswere incubatedwith buffer orwith
buffer supplemented with UCPH-101 or TBOA for various time periods, and washed for 3 15
min before determination of specific [ 3H]-D-Asp uptake (n	 3). D, E, Glu and TBOA do not
alleviate the long-lasting effects of UCPH-101 preincubation on EAAT1 function. D, EAAT1-
HEK293 cells were incubated for 1minwith buffer (f) or with buffer supplementedwith 3mM
Glu () or 300M TBOA (F), then incubated for 2 min with various concentrations of UCPH-
101 in buffer (f) or in buffer supplementedwith 3mMGlu () or 300M TBOA (F), and then
washed for 3 15min before determination of specific [ 3H]-D-Asp uptake (n	 3). E, EAAT1-
HEK293 cells were incubated for 1minwith various concentrations of UCPH-101 in buffer, then
incubated for 2minwith buffer (f) orwith buffer supplementedwith 3mMGlu () or 300M
TBOA (F), and thenwashed for 315minbefore determination of specific [ 3H]-D-Asp uptake
(n	 4). F, Preincubation with UCPH-101 does not change the cell surface expression levels of
EAAT1 andGLAST. HA-EAAT1- or HA-GLAST-expressing tsA201 cellswere incubatedwith buffer
or buffer supplementedwith 100M UCPH-101 for 15min, andwashed for 3 15min before
the ELISA was performed (n	 4). The cell surface expression of neither HA-EAAT1 nor HA-
GLAST in buffer- and UCPH-101-pretreated cells differed significantly. Preexposure of cells to
the inhibitor resulted in a small but significant decrease in total expression levels (ANOVA:
HA-EAAT1: p	 0.048, HA-GLAST: p	 0.049). G, Effects on EAAT1 function of preincubation
with UCPH-101 and five analogs. Left, EAAT1-HEK293 cells were preincubatedwith buffer sup-
plementedwith various concentrations of the inhibitors for 15min, andwashed for 3 15min
before determination of specific [ 3H]-D-Asp uptake (n	 4). Right, Relationship between pIC50
values for the UCPH-101, UCPH-102, UCPH-100, and 1 in the [ 3H]-D-Asp uptake assay and the
pIC50 values obtained for the compounds in thepreincubation experiment. TheR
2 values for the
fittings of the data for UCPH-100, 1, and UCPH-102 (black line) and the data for UCPH-100, 1,
UCPH-102, and UCPH-101 (gray line) are given.
Table 1. Physicochemical characteristics of UCPH-101 and five analogs and their functional properties at EAAT1-HEK293 cells in the [ 3H]-D-Asp uptake assay and in the
preincubation experiments. The logP values (octanol/water) and total polar surface area (tPSA) were calculated in MOE. IC50 values obtained for the inhibitors in the [
3H]-
D-Asp uptake assay and in the preincubation experiments are given inMwith pIC50 SEM values in parentheses
Compound logP tPSA
[ 3H]-D-Asp uptakea
IC50 (M)
(pIC50 SEM)
Preincubation
IC50 (M)
(pIC50 SEM)
UCPH-101 3.94 151 0.66 (6.18 0.08) 0.23 (6.64 0.15)
UCPH-102 2.71 156 0.42 (6.47 0.21) 20 (4.71 0.20)
UCPH-100 2.76 150 3.9 (5.48 0.20) 
300 (
3.5)
1 3.45 155 0.87 (6.11 0.15) 
30 (
4.5)
2 2.42 262 11 (4.97 0.05) 300 (3.5)
3 1.49 156 9.2 (5.04 0.05) 300 (3.5)
Results from the preincubation experiments are based on 3–4 individual experiments performed in duplicate as described in Materials and Methods and in the legend to Figure 3G.
a The IC50 values for the ligands in the [
3H]-D-Asp uptake assay have been reported previously: UCPH-101,2 and3 (Jensen et al., 2009), UCPH-102 andUCPH-100 (Erichsen et al., 2010) and1 (M.N. Erichsen, J. Hansen, B. Abrahamsen, T.H.V.
Huynh, C.S. Demmer, A.A. Jensen, and L. Bunch, unpublished observations).
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UCPH-100, and 1 in the [3H]-D-Asp up-
take assay and in the preincubation exper-
iment is characterized by an R2 value of
0.96, which is reduced to 0.31 when the
UCPH-101 data are included (Fig. 3G).
The observed different duration of the
EAAT1 inhibition exerted by the six ana-
logs could potentially arise from differ-
ences in the physicochemical properties of
the compounds. However, the calculated
tPSA values for UCPH-101, UCPH-102,
UCPH-101, 1, and 3 are essentially iden-
tical, and although UCPH-101 is themost
lipophilic compound of the series, the cal-
culated logP value of analog 1 is compara-
ble with that of UCPH-101 (3.45 and 3.94,
respectively; Table 1). Furthermore, it is
not possible to pinpoint a single struc-
tural feature in the UCPH-101 molecule
accountable for its long-lasting effects
on EAAT1: Comparisons of the IC50
value displayed by UCPH-101 to those
of UCPH-100 and 2 in the uptake assay
and of the IC50 values of UCPH-102 and
1 to that of 3 identify the 1-naphthalene
or 1-o-biphenyl groups in these inhibi-
tors as key for their higher inhibitory
potencies at EAAT1 (Fig. 1; Table 1).
However, the presence of a 1-naph-
thalene group in both UCPH-101 and
UCPH-102 clearly demonstrates that the
lipophilic 7-substituent is not the sole de-
terminant of the sustained inhibition associatedwithUCPH-101.
The 4-substituent in the chromene scaffold is the obvious other
candidate, as UCPH-101 and UCPH-102 only differ when it
comes to their respective 4-methoxyphenyl andmethyl groups in
this position (Fig. 1). However, because the IC50 values of 2 and
UCPH-100 in the preincubation experiment correlate with their
respective potencies in the [3H]-D-Asp uptake assay, the presence
of a 4-methoxyphenyl or a phenyl group in this position is clearly
not sufficient to induce the long-lasting inhibition characteristic
in these ligands (Fig. 3G). Hence, this unique property of UCPH-
101 appears to arise from system dynamics induced by small-
molecule-protein interactions.
UCPH-101 and UCPH-102 display significantly different
blocking and unblocking kinetics at EAAT1
To determine the binding kinetics of UCPH-101 and UCPH-102
at EAAT1, the time course of EAAT1 current amplitudes was
recorded at a fixed voltage step of 145 mV upon application
(wash in) or removal (wash out) of 1 MUCPH-101 (Fig. 4A) or
1 M UCPH-102 (Fig. 4B). The experiments were performed in
the presence of saturating concentrations of Glu. Application of 1
MUCPH-101 or 1MUCPH-102 resulted inmonoexponential
decreases of the current amplitude with time constants of 10.5
1.4 s (UCPH-101, n 	 11) and 4.0  1.2 s (UCPH-102, n 	 6)
(Fig. 4A left and 4B left, respectively). After reaching steady state,
the perfusion was changed to inhibitor-free solution to evaluate
the time course of the unbinding of UCPH-101 and UCPH-102
from EAAT1 (Fig. 4A right and 4B right, respectively). UCPH-
101 unblocking occurred on a very slow time scale ( 	 740 
100 s, n 	 9), whereas the block induced by UCPH-102 was
relieved much faster ( 	 55.7  4.8 s, n 	 6). Because full
recovery of the EAAT current amplitude occurred only rarely
after UCPH-101 block, the unblocking time constant for this
compound might be underestimated.
UCPH-101 exhibits noncompetitive inhibition of
EAAT1 function
The nature of the inhibition exerted byUCPH-101 at EAAT1was
investigated in the FMP assay and compared with that of TBOA.
The pharmacological characteristics of the EAAT1-HEK293 cell
line in the FMP assay have previously been shown to be in good
agreement with those observed for the transporter in conven-
tional uptake assays and electrophysiological setups (Jensen and
Bra¨uner-Osborne, 2004). In concordance with a previous study
(Shimamoto et al., 1998) and as reported for TBOA at EAAT2
(Jensen and Bra¨uner-Osborne, 2004), the functional profile of
TBOA at EAAT1 in the FMP assay was characteristic of that of a
competitive inhibitor. Glu exhibited increasing Km (EC50) values
at the transporter in the presence of increasing TBOA concentra-
tions, whereas themaximal response (Rmax) elicited by the substrate
in the assay was not significantly changed (Fig. 5A). Conversely, the
IC50 valuesdetermined forTBOAatEAAT1wereverydependenton
the Glu concentrations used in the assay (Fig. 5B). In accordance
with the principle of competitive inhibition, Ki values calculated for
TBOAbased on IC50 values obtained using differentGlu concentra-
tions were very similar (Fig. 5B).
The EAAT1 inhibition exerted by UCPH-101 was different
from that of TBOA. The presence of UCPH-101 in the FMP assay
did not change the Km (EC50) values of Glu at the transporter
substantially, whereas the maximal response elicited by the sub-
strate was decreased with increasing concentrations of the inhib-
itor (Fig. 5A). Furthermore, the IC50 values determined for
Figure 4. Unbinding of UCPH-101 and UCPH-102 from EAAT1 occurs on different time scales. A, B, Left, EAAT1 current-
responses to application of 1MUCPH-101 (A) or 1MUCPH-102 (B) at repetitive voltage steps of145mV recordedwith a time
interval of 1 s between successive steps. Anion current peak amplitudes decayedwith time constants of 10.51.4 s (n	11) after
application of UCPH-101 and 4.0 1.2 s (n	 6) after application of UCPH-102. Right, Unbinding of UCPH-101 (A) and UCPH-102
(B) from EAAT1 induced by application of inhibitor-free solution to cells expressing the transporter. Peak current amplitudes
increasedwith time constants of 740.4100 s for UCPH-101 (n	9) and55.74.8 s for UCPH-102 (n	6). Currentswere fitted
with an exponential function. Data are given as mean SE. Insets, Representative current recordings.
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UCPH-101 at EAAT1 using six different (S)-Glu concentrations
were similar (Fig. 5B).
The profile exhibited by UCPH-101 in the FMP assay was
supported by patch-clamp experiments, where similar concen-
tration dependences of block by UCPH-101 were observed in the
presence of different Glu concentrations. Figure 6 shows repre-
sentative whole-cell recordings of EAAT1 with external solution
containing 10 mM Glu (Fig. 6A) or 0 mM Glu (Fig. 6B) in the
absence (top) or presence (bottom) of 10 M UCPH-101. The
concentration dependence of block by UCPH-101 in presence of
variousGlu concentrations is shown in Figure 6C. KD values
0.3
M were obtained for UCPH-101 in these
experiments (with 0.1 mM Glu: KD UCPH-
101	 0.29 0.03 M, Hill	 1.18 0.11,
n  5; with 0.5 mM Glu: KD UCPH-101 	
0.34 0.03 M, Hill	 1.3 0.13, n 9;
with 10 mM Glu: KD UCPH-101 	 0.35 
0.03 M, Hill 	 1.29  0.14, n 	 6).
EAAT1 anion currents were also blocked
in the absence of Glu (KD UCPH-101 	
0.28  0.09 M; Hill 	 0.78  0.17, n 
6), which suggests that UCPH-101 associ-
ates with EAAT1 in its outward-facing
conformation. Without Glu present,
EAAT1 anion currents are much smaller,
resulting in larger contributions of back-
ground currents and apparently less com-
plete block by UCPH-101. In conclusion,
UCPH-101 displayed all the characteris-
tics of a noncompetitive inhibitor at
EAAT1.
Identification of the allosteric site
targeted by UCPH-101 in GLAST
The noncompetitive inhibition exhibited
by UCPH-101 at EAAT1 prompted us to
search for its putative allosteric binding
site in the transporter. This was done in a
multistep iterative process, where func-
tional properties of Glu, TBOA, and
UCPH-101 were determined at chimeras
of GLAST and GLT-1 and at GLAST and
GLT-1mutants in the [3H]-D-Asp uptake
assay. In the early stages of the project, the
constructed chimeras and mutants were
transiently expressed in tsA201 cells and
screened for function. Major findings
from the experiments were subsequently
confirmed at transporters stably ex-
pressed in polyclonal HEK293 cell lines,
and later steps in the project were per-
formed exclusively at these stable poly-
clonal cells.
In the first phase of the project, Glu,
TBOA, and UCPH-101 were character-
ized functionally at a considerable
number of GLAST/GLT-1 chimeras in
[3H]-D-Asp uptake assay. Unfortunately,
most of these chimeras turned out to be
nonfunctional, as no significant [3H]-D-
Asp uptake could be measured in tsA201
cells expressing them (Fig. 7A). This was
very much in line with previous observa-
tions made by Vandenberg and colleagues in a study of a series of
EAAT1/EAAT2 chimeras (Mitrovic et al., 1998). The reasons for
the observed nonfunctionality of these chimeras were not inves-
tigated further. Important for this study, the chimeras N76,
N354, N403, and N461 were functional, and Glu and TBOA dis-
played similar IC50 values at these chimeras as those exhibited at
WTGLAST andWTGLT-1 (Fig. 7B; Table 2, section I).Whereas
UCPH-101 was inactive at N76, it inhibited [3H]-D-Asp uptake
through the other three chimeras with IC50 values not signifi-
cantly different from that at WT GLAST (Table 2, section I). The
WT GLAST-like activity displayed by UCPH-101 at the N354
Figure 6. UCPH-101 dependence of EAAT1 in the presence of various Glu concentrations.A,B, EAAT1whole-cell currents in the
presenceof 10mMexternal Glu (A) or in the absenceof external Glu (B)withoutUCPH-101 (top) orwith10MUCPH-101 (bottom).
C, UCPH-101 concentration dependence of EAAT1 currents at a voltage step of185 mV. Data were normalized to the current in
absence of external UCPH-101, and mean current amplitudes from different cells were fitted with a Hill equation.
Figure 5. The nature of inhibition exerted by TBOA and UCPH-101 at EAAT1-HEK293 cells in the FLIPR Membrane
Potential Blue assay. A, Concentration–response curves for Glu in the absence or the presence of five different concentra-
tions of TBOA or UCPH-101. B, Concentration–inhibition curves for TBOA and UCPH-101 using six different Glu concentra-
tions. Ki values for TBOA were calculated using the Cheng-Prusoff equation [Ki	 IC50/(1 [Glu]/Km)] (Craig, 1993). The
figures show data from single representative experiments of a total of 3 or 4 experiments, and data are given as mean
SD of duplicate determinations.
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chimera was particularly informative, as it demonstrated that
all molecular determinants for the subtype selectivity of the
inhibitor reside within the Met 1-Gln 354 region of GLAST (Fig.
7B, C). To further narrow down the GLAST region containing
these determinants, several additional GLAST/GLT-1 chime-
ras were constructed (Fig. 7A), but all of these were nonfunc-
tional. Thus, we took on another approach in our search for
the UCPH-101 binding site.
Alignment of the amino acid sequences of human EAAT1,
EAAT2, and EAAT3 and rat GLAST, GLT-1, and EAAC1 identi-
fies a total of 104 residues in the Phe50-Gln354 region spanning
the TM1 to the first half ofHP1a of GLAST, which are identical in
EAAT1 but different in the four other transporters. In the second
phase of the project, 75 of these residues inGLAST (located in the
TM1-TM4b and TM4c-HP1a segments) were mutated to the
corresponding GLT-1 residues (Fig. 8), and UCPH-101 was
tested at the mutants transiently expressed in tsA201 cells. The
most notable observation made in this screening was the pro-
nounced impairment of the inhibitory activity of UCPH-101
brought on by the F255I mutation in GLAST, since Glu and
TBOA exhibited IC50 values at the mutant not significantly dif-
ferent from those at WT GLAST (data not shown). This finding
was subsequently reproduced in polyclonal HEK293 cells ex-
pressing the mutant (Fig. 9; Table 2, section II).
Mapping of the UCPH-101 binding site in GLAST
The detrimental effects of the F255I mutation on UCPH-101
inhibition of GLAST prompted us to search for additional
residues important for the activity of the inhibitor in the vi-
cinity of Phe 255. The residue is located in the TM4c helix of
GLAST and corresponds to the Ile 163 residue in the GltPh
transporter (Yernool et al., 2004). In the third phase of the
search for interaction partners for UCPH-101, we applied the
crystal structure of GltPh in its unbound, outward-facing state
(Boudker et al., 2007) to identify residues located in the vicin-
ity of this residue. In some mutants, stretches of residues were
mutated to the corresponding residues in GLT-1 but in most
mutants single residues were substituted with amino acids
expected to significantly alter their respective putative inter-
actions with UCPH-101. Residues identified as important for
UCPH-101 activity were subsequently subjected to additional
mutations to probe the nature of and the spatial requirements
for the putative interactions.
The functional properties ofGlu, TBOA, andUCPH-101were
determined at polyclonal HEK293 cells stably expressing 86 dif-
ferentGLASTmutants in the [3H]-D-Asp uptake assay. The func-
tional properties of the mutants are given in Table 2, sections
II–VI, concentration-inhibition curves for UCPH-101 at selected
mutants are given in Figure 9, and IC50 values and degrees of
Figure 7. The selectivity determinant for UCPH-101 resides within theMet 1-Gln 354 region of GLAST. A, Selected nonfunctional GLAST/GLT-1 chimeras. GLAST and GLT-1 regions in the chimeras
are given in green and red, respectively. The prefixes N and C in the chimera names refer to the presence of GLAST parts in the N- and C-terminal, respectively, and the numbers refer to the first or
last GLAST residue at the fusion point of C- and N-chimeras, respectively. B, Topology of WT GLAST and WT GLT-1 and the functional GLAST/GLT-1 chimeras N76, N354, N403, and N461. C,
Concentration–inhibition curves for Glu, TBOA, and UCPH-101 at WT GLAST, WT GLT-1, and chimera N354 stably expressed in polyclonal HEK293 cells in the [ 3H]-D-Asp uptake assay (n	 4).
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Table 2. Functional characteristics ofGlu, TBOA, andUCPH-101atWTGLAST,WTGLT-1, GLAST/GLT-1 chimeras, andGLASTandGLT-1mutants stably expressed inpolyclonalHEK293
cells in the [3H]-D-Aspuptakeassay (using100nM [3H]-D-Aspas tracer concentration). Theposition(s) of themutation(s) introduced in the respectivemutant transporters are
indicated togetherwith the corresponding residue(s) inGltPh. The IC50 values forGlu, TBOA, andUCPH-101aregiven inMwithpIC50 SEMvalues inparentheses. Themaximal
inhibitiondegreesbyUCPH-101at the respective transporters aregivenas% SEMof themaximal inhibitionexertedbyGluat the sametransporter.Maximal inhibition
percentages in the90–100%rangeare statedas “Complete inhibition,” andmaximal inhibitionpercentagesbelow20%as “No inhibition.”
Transporter
Position of Mutation
(Residue in GltPh )
Glu IC50 (M)
(pIC50 SEM)
TBOA IC50 (M)
(pIC50 SEM)
UCPH-101 IC50 (M)
(pIC50 SEM)
UCPH-101
Maximal inhibition
(% SEM)
WT GLAST — 18 (4.74 0.01) 2.5 (5.60 0.03) 0.49 (6.31 0.05) Complete inhibition
WT GLT-1 — 31 (4.51 0.02) 1.4 (5.86 0.03) 100 (4.0) No inhibition
I. GLAST/GLT-1 CHIMERAS
Chimera N76 GLASTM1-R76/GLT-1 V74-I562 35 (4.46 0.05) 1.9 (5.72 0.09) 100 (4.0) No inhibition
Chimera N354 GLASTM1-Q354/GLT-1 A353-I562 23 (4.64 0.06) 2.1 (5.68 0.10) 0.51 (6.29 0.07) Complete inhibition
Chimera N403 GLASTM1-A403/GLT-1 L402-I562 33 (4.48 0.10) 3.1 (5.51 0.11) 0.86 (6.07 0.13) Complete inhibition
Chimera N461 GLASTM1-P461/GLT-1 T460-I562 24 (4.62 0.08) 3.5 (5.46 0.16) 1.1 (5.97 0.08) Complete inhibition
II. GLAST MUTANTS (TM4c)
V247I/V248G TM4c (I255/F156) 21 (4.69 0.11) 3.4 (5.48 0.03) 0.51 (6.29 0.14) Complete inhibition
V248F TM4c (F156) 17 (4.74 0.07) 4.6 (5.34 0.08) 0.51 (6.30 0.07) Complete inhibition
S250F/M251I/C252A TM4c (A158/I159/I160) 14 (4.87 0.10) 1.8 (5.74 0.06) 0.82 (6.07 0.12) Complete inhibition
M251G TM4c (I159) 12 (4.91 0.04) 6.5 (5.19 0.03) 
30 (
4.5) ND
M251L TM4c (I159) 29 (4.53 0.09) 2.9 (5.54 0.07) 0.81 (6.09 0.03) Complete inhibition
M251I TM4c (I159) 24 (4.60 0.03) 2.7 (5.57 0.05) 0.51 (6.29 0.02) Complete inhibition
M251F TM4c(I159) 25 (4.61 0.03) 3.2 (5.50 0.11) 0.62 (6.21 0.08) Complete inhibition
C252G TM4c(I160) 12 (4.92 0.07) 2.3 (5.64 0.12) 0.89 (6.05 0.12) Complete inhibition
C252I TM4c (I160) 21 (4.68 0.05) 4.5 (5.34 0.03) 1.9 (6.42 0.09) Complete inhibition
F255A TM4c (I163) 9.9 (5.01 0.13) 2.6 (5.58 0.08) 0.95 (6.02 0.13)a 87 2.8
F255V TM4c(I163) 12 (4.92 0.13) 2.0 (5.71 0.13) 0.62 (6.32 0.09)a 79 1.6
F255L TM4c (I163) 12 (4.93 0.12) 4.8 (5.32 0.12) 1.6 (5.80 0.14)a 78 4.2
F255I TM4c (I163) 23 (4.68 0.08) 4.3 (5.37 0.12) 100 (4.0) No inhibition
F255N TM4c (I163) 14 (4.85 0.07) 3.6 (5.45 0.14) 0.48 (6.31 0.01) Complete inhibition
F255W TM4c (I163) 15 (4.82 0.07) 3.5 (5.45 0.15) 0.58 (6.25 0.09) Complete inhibition
F255R TM4c (I163) 20 (4.70 0.07) 2.0 (5.70 0.04) 0.53 (6.27 0.06) Complete inhibition
V256A/I257M/N259K TM4c (A164/I165/Y167) 14 (4.86 0.15) 2.9 (5.53 0.06) 0.92 (6.04 0.14)a 78 4.9
III. GLAST MUTANTS (TM3)
S116F TM3 (L78) 28 (4.55 0.04) 3.2 (5.49 0.03) 0.80 (6.10 0.01)a 53 4.1
G117F TM3 (G79) 24 (4.62 0.11) 2.2 (5.66 0.08) 0.45 (6.34 0.09) Complete inhibition
G117L/K118A/M119A TM3 (G79/R80/V81) 18 (4.74 0.10) 4.3 (5.37 0.04) 1.4 (5.85 0.05) Complete inhibition
G120L/M121A/R122A TM3 (G82/V83/K84) 11 (4.94 0.03) 3.2 (5.49 0.15) 100 (4.0) No inhibition
G120A TM3 (G82) 7.5 (5.12 0.16) 2.9 (5.54 0.09) 100 (4.0)a 22 3.1
G120V TM3 (G82) 8.6 (5.06 0.07) 4.1 (5.39 0.13) 100 (4.0) No inhibition
G120L TM3 (G82) 14 (4.89 0.08) 2.8 (5.56 0.14) 100 (4.0) No inhibition
M121A TM3 (V83) 18 (4.74 0.03) 3.1 (5.51 0.11) 1.8 (6.16 0.20) Complete inhibition
R122A TM3 (K84) 18 (4.74 0.06) 4.3 (5.37 0.07) 0.69 (5.76 0.18)a 87 3.1
A123L/V124G/V125G TM3 (I85/V86/V87) 12 (4.91 0.06) 2.2 (5.66 0.13) 
1 (
6.0)a 47 11
A123G TM3 (I85) 16 (4.79 0.08) 4.8 (5.31 0.02) 1.3 (5.89 0.09)a 72 5.2
A123I TM3 (I85) 24 (4.60 0.09) 8.7 (5.06 0.03) 1.2 (5.93 0.08) Complete inhibition
A123F TM3 (I85) 23 (4.63 0.03) 8.7 (5.06 0.09) 100 (4.0) No inhibition
V124G TM3 (V86) 11 (4.96 0.11) 6.5 (5.18 0.15) 0.91 (6.04 0.12)a 80 4.1
V124F TM3 (V86) 21 (4.69 0.04) 6.6 (5.18 0.03) 1.7 (5.76 0.10) Complete inhibition
Y126A/Y127A TM3 (Y88/Y89) 6.4 (5.19 0.05) 2.7 (5.56 0.18) 0.44 (6.36 0.04)a 85 3.8
Y126G TM3 (Y88) 18 (4.75 0.04) 3.2 (5.49 0.02) 0.27 (6.57 0.11) Complete inhibition
Y127G TM3 (Y89) 13 (4.89 0.08) 14 (4.84 0.07) 0.62 (6.21 0.04)a 23 2.8
Y127L TM3 (Y89) 8.2 (5.09 0.13) 5.1 (5.30 0.15) 1.5 (5.82 0.17)a 54 5.4
Y127I TM3 (Y89) 24 (4.69 0.04) 1.6 (5.85 0.03) 2.9 (5.54 0.08)a 45 4.7
Y127F TM3 (Y89) 9.5 (5.02 0.04) 2.8 (5.56 0.03) 1.1 (5.96 0.13) Complete inhibition
Y127R TM3 (Y89) 14 (4.84 0.12) 2.3 (5.63 0.16) 2.2 (5.65 0.09)a 65 5.7
IV. GLAST MUTANTS (TM7a)
R385F TM7a (G297) 12 (4.91 0.06) 3.4 (5.47 0.01) 0.32 (6.50 0.09) Complete inhibition
I386G TM7a (I298) 16 (4.79 0.03) 2.4 (5.62 0.04) 0.22 (6.66 0.07) Complete inhibition
I386F TM7a (I298) 19 (4.73 0.11) 3.0 (5.52 0.03) 0.39 (6.41 0.09) Complete inhibition
F389A TM7a (F301) 9.2 (5.04 0.07) 9.2 (5.04 0.11) 0.21 (6.69 0.18)a 35 4.3
F389L TM7a (F301) 15 (4.83 0.06) 2.0 (5.60 0.19) 0.28 (6.55 0.11)a 27 2.9
F389Q TM7a (F301) 12 (4.92 0.04) 13 (4.89 0.03) 0.37 (6.43 0.09)a 37 4.9
F389T TM7a (F301) 17 (4.77 0.03) 7.4 (5.13 0.04) 100 (4.0) No inhibition
F389W TM7a (F301) 15 (4.82 0.05) 4.2 (5.38 0.08) 100 (4.0) No inhibition
V390G TM7a (T302) 24 (4.62 0.07) 5.1 (5.29 0.11) 0.55 (6.26 0.14) Complete inhibition
(Table continues.)
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maximal inhibition exerted byUCPH-101 at selectedmutants are
summarized in Figure 10. The IC50 values displayed by Glu at the
86 mutants ranged from 7.5 to 28 M and thus did not differ
substantially from that exhibited at WT GLAST (IC50 	 18 M;
Table 2). The same was true for TBOA for the majority of mu-
tants, as the inhibitor at 77 of the 86 GLAST mutants displayed
IC50 values less than threefold different from its IC50 at WT
GLAST (Table 2).
In contrast to the inconsiderable effects of the mutations on
the properties of Glu andTBOAatGLAST,UCPH-101-mediated
inhibition of uptake through GLAST was dramatically impaired
bymutations of seven specific residues localized in the proximity
of Phe255, more specifically in the TM3, TM4c, and TM7a helices
(Figs. 9 and 10). Interestingly, mutations of the seven residues
gave rise to highly differential effects on the inhibitory potency
and/or efficacy of UCPH-101 at GLAST. Several mutations re-
sulted in reduced inhibitory potencies of UCPH-101 or com-
pletely eliminated the activity of the inhibitor at the transporter
(Figs. 9 and 10; Table 2). However, IC50 values exhibited by
UCPH-101 at some of the mutants containing substitutions of
the residues Tyr127, Phe389, or Val393 were similar or only slightly
higher than that at WT GLAST, whereas the efficacies displayed
Table 2. Continued
Transporter
Position of Mutation
(Residue in GltPh )
Glu IC50 (M)
(pIC50 SEM)
TBOA IC50 (M)
(pIC50 SEM)
UCPH-101 IC50 (M)
(pIC50 SEM)
UCPH-101
Maximal inhibition
(% SEM)
V393G TM7a (L305) 15 (4.82 0.01) 4.2 (5.38 0.08) 0.41 (6.39 0.02) Complete inhibition
V393I TM7a (L305) 19 (4.71 0.05) 6.8 (5.17 0.03) 1.9 (5.72 0.01)a 85 4.9
V393T TM7a (L305) 21 (4.67 0.02) 4.7 (5.33 0.03) 100 (4.0) No inhibition
V393Q TM7a (L305) 12 (4.91 0.04) 5.9 (5.23 0.09) 0.21 (6.67 0.08)a 54 4.1
V393F TM7a (L305) 13 (4.89 0.06) 5.4 (5.27 0.05) 
0.3 (
6.5)a 41 2.7
T396G TM7a (T308) 27 (4.57 0.07) 6.2 (5.21 0.14) 0.47 (6.33 0.10) Complete inhibition
I397G TM7a (I309) 13 (4.90 0.06) 4.8 (5.32 0.00.9) 0.34 (6.46 0.04)a 87 4.3
I397F TM7a (I309) 10 (5.00 0.04) 3.8 (5.42 0.02) 0.56 (6.38 0.08) Complete inhibition
V. GLAST MUTANTS (TM2, TM2/3 LOOP, TM5 and TM8)
L104A/V105A/T106A TM2 (L66/V67/V68) 11 (4.98 0.13) 5.4 (5.27 0.05) 0.33 (6.48 0.19) Complete inhibition
M108L/A109S/A110G/S113A TM2/3 Loop (A70/A71/S72/A76) 16 (4.79 0.03) 3.2 (5.59 0.08) 0.93 (6.03 0.15) Complete inhibition
G107V/M108A TM2/3 Loop (G69/A70) 8.4 (5.08 0.04) 5.9 (5.22 0.12) 2.3 (5.64 0.17)a 81 5.3
A109I TM2/3 Loop (A71) 16 (4.81 0.04) 9.4 (5.03 0.09) 2.6 (5.58 0.09)a 83 2.3
A109L TM2/3 Loop (A71) 10 (5.01 0.13) 4.7 (4.32 0.09) 1.2 (5.92 0.16)a 69 4.1
A109F TM2/3 Loop (A71) 13 (4.88 0.06) 13 (4.88 0.06) 1.6 (5.79 0.12)a 87 3.4
A110L TM2/3 Loop (S72) 9.8 (5.01 0.15) 3.6 (5.44 0.10) 0.91 (6.04 0.11) Complete inhibition
L111A TM2/3 Loop (I73) 8.7 (5.06 0.09) 2.2 (5.66 0.14) 1.5 (5.83 0.10) Complete inhibition
D112A TM2/3 Loop (P75) 8.8 (5.06 0.10) 5.1 (5.29 0.10) 
1 (
6.0)a 55 7.1
S113G TM2/3 Loop (A76) 15 (4.83 0.06) 4.6 (5.34 0.16) 1.1 (6.34 0.18)a 85 3.1
S113L TM2/3 Loop (A76) 11 (4.97 0.18) 3.3 (5.48 0.07) 0.46 (6.34 0.18) Complete inhibition
K114A/A115G TM2/3 Loop (R77) 13 (4.89 0.04) 2.8 (5.56 0.07) 0.77 (6.12 0.12) Complete inhibition
G264A/Q265K/A266L/
L267M/R268V TM5 (A180/E181/T182/L183/L184L) 9.1 (5.04 0.06) 2.7 (5.57 0.17) 0.54 (6.27 0.10) Complete inhibition
D272N/S273I TM5 (N188/G189) 16 (4.79 0.04) 4.3 (5.37 0.15) 1.2 (5.95 0.18) Complete inhibition
A277I/I278V/R280K/A283I/
V284M TM5 (A193/M194/K196/N199/G200) 7.8 (5.11 0.06) 9.7 (5.01 0.18) 0.65 (6.19 0.17)a 88 1.9
R280A/L281A TM5 (K196/I197) 15 (4.83 0.10) 6.6 (5.18 0.10) 0.33 (6.48 0.15) Complete inhibition
G490L TM8 (G408) 19 (4.72 0.05) 2.6 (5.58 0.10) 0.31 (6.51 0.09) Complete inhibition
G490F TM8 (G408) 14 (4.86 0.06) 2.1 (5.67 0.13) 0.22 (6.66 0.10)a 81 2.6
V494F TM8 (V412) 12 (4.92 0.06) 3.1 (5.51 0.07) 1.0 (6.05 0.16) Complete inhibition
VI. GLAST MUTANTS (TM2 and TM5 IN NEIGHBORINGMONOMER)
F83G/P84G/G85L TM2 (P45/F46/G47) 13 (4.87 0.08) 2.2 (5.65 0.03) 0.35 (6.45 0.13) Complete inhibition
E86G/L87G/L88G TM2 (D48/L49/F50) 15 (4.84 0.04) 2.2 (5.27 0.17) 0.46 (6.34 0.15) Complete inhibition
M79G/R80G/M81G TM2 (V51/R52/L53) 23 (4.64 0.08) 1.9 (5.72 0.12) 0.91 (6.04 0.17) Complete inhibition
L92G/Q93G TM2 (L54/K55) 13 (4.88 0.03) 6.0 (5.21 0.03) 0.77 (6.12 0.07) Complete inhibition
M94G/L95G TM2 (M56/L57) 14 (4.85 0.01) 14 (4.86 0.04) 1.0 (5.99 0.08)a 87 3.4
A277L/I278G/M279G TM5 (A193/M194/Y195) 16 (4.80 0.02) 3.4 (5.46 0.09) 0.78 (6.11 0.20) Complete inhibition
R280G/L281G/V282G TM5 (K196/I197/V198) 20 (4.71 0.05) 3.2 (5.49 0.08) 0.69 (6.16 0.14) Complete inhibition
A283L/V284G/I285G TM5 (N199/G200/V201) 26 (4.58 0.05) 25 (4.60 0.07) 2.5 (5.60 0.15)a 85 5.1
M286G/W287G/Y288G TM5 (M202/Q203/Y204) 21 (4.68 0.06) 7.0 (5.15 0.06) 1.4 (5.86 0.20) Complete inhibition
A289G/P290G TM5 (A205/P206) 17 (4.78 0.04) 2.1 (5.68 0.09) 0.50 (6.30 0.16) Complete inhibition
L291G/G292L TM5 (I207/G208) 18 (4.75 0.04) 8.6 (5.07 0.12) 3.0 (5.53 0.03)a 81 2.9
VII. GLT-1 MUTANTS
I249M TM4c (I159) 44 (4.36 0.07) 3.5 (5.46 0.18) 100 (4.0) No inhibition
I253F TM4c (I163) 38 (4.43 0.06) 3.1 (5.50 0.11) 100 (4.0) No inhibition
I249M/I253F TM4c(I159/I163) 33 (4.48 0.09) 1.9 (5.71 0.12) 100 (4.0) No inhibition
The polyclonal cell lines were generated and the [ 3H]-D-Asp uptake assay was performed as described in Materials and Methods. Data are the means of 3–20 individual experiments performed in duplicate.—, Not applicable; ND, not
determinable.
a UCHP-101 did not inhibit specific [ 3H]-D-Asp uptake in cells expressing through this mutant completely, and thus the IC50 value for UCPH-101 at this mutant represents the concentration yielding 50% of the observed inhibition.
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by the inhibitor (i.e., the maximal degrees of inhibition of [3H]-
D-Asp uptake) were dramatically reduced (Figs. 9 and 10; Table
2). The potential reasons for and implications of these differential
effects of the mutations on UCPH-101 potency and efficacy will
be addressed in the Discussion.
TM4c
In contrast to the dramatic effect of the F255I mutation, intro-
duction of several other amino acid residues (Ala, Val, Leu, Asn,
Arg, andTrp) in this position did not result in substantial impair-
ments of UCPH-101 activity at GLAST (Fig. 9; Table 2, section
Figure 8. Alignment of amino acid sequences of rat GLAST and GLT-1 (extracted from an alignment of human EAAT1, EAAT2, and EAAT3 and rat GLAST, GLT-1, and EAAC1). The TM1– 8
and HP1–HP2 regions are specified above the sequences. Residues in the Phe 50-Gln 354 segment of GLAST mutated in the preliminary mutagenesis study () and residues mutated in
mutants stably expressed in polyclonal HEK293 in later stages of the project (*) are indicated below the sequences. The fusion points of GLAST/GLT-1 chimeras N76, N354, N403, and N461
and the site of HA-tag insertion in GLAST are given. The Gly 120, Ala 123, Tyr 127, Met 251, Phe 255, Phe 389, and Val 393 residues in GLAST where selected mutations were found to affect
UCPH-101 activity are circled.
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II). Removal of the side chain of the
Met251 residue situated one -helix turn
(4 residues) above Phe255 (M251G) re-
sulted in a significant increase in the
UCPH-101 IC50, whereas introduction of
Leu, Ile, or Phe residues in this position
had negligible effects on inhibitor activity
(Table 2, section II). Importantly, UCPH-
101 displayed WT-like IC50 values at mu-
tants containing mutations of the
neighboring Cys252 residue and at mu-
tants with substitutions of residues yet an-
other helix turn below Phe255 (V247I/
V248G and V248F) or residues located
above the residue (V256A/I257M/
N259K) (Table 2, section II). Thus, the
distribution of residues found to be im-
portant for UCPH-101 activity in TM4c
(Met251 and Phe255) is in agreement with
the -helical structure of the domain.
TM3
Conservative mutations of the Gly120 res-
idue in the cytoplasmic part of TM3 were
found to abolish the activity of UCPH-
101 at GLAST completely (G120V,
G120L) or almost completely (G120A)
(Fig. 9; Table 2, section III). Mutations of
Ser116 and Gly117 residues located one he-
lix turn below Gly120 did not change
UCPH-101 activity at GLAST substan-
tially. In contrast, some mutations of
Ala123 and Tyr127 situated one and two
helix turns above Gly120, respectively, im-
paired UCPH-101 inhibition significantly
(A123F, Y127G, Y127L), whereas others
did not (A123G, A123I, Y123I, Y123F,
Y127R). Mutations of other residues in
the Gly120-Tyr127 segment (Met121,
Arg122, Val124, andTyr126) did not impact
the UCPH-101 activity at the transporter
(Table 2, section III). Thus, analogously to
the pattern observed for TM4c, the distri-
bution of residues of importance for
UCPH-101 activity in TM3was consistent
with the -helical structure of TM3.
TM7a
In the TM7a helix, the Phe389 residue turned out to be essential
for UCPH-101 activity, as introduction of Ala, Leu, Thr, Gln, and
Trp residues in this position all had detrimental effects on the inhi-
bition mediated by the ligand (Fig. 9; Table 2, section IV). Whereas
removal of the side chain and a conservative mutation of the Val393
residue situated one helix turn above Phe389 had little impact on
UCPH-101 activity (V393G and V393I), introduction of hydro-
philic or aromatic residues in this position resulted in significantly
reduced the inhibitorypotencyand/orefficacyof the ligand(V393Q,
V393T, V393F).Mutations introduced one helix turn below Phe389
(R385F, I386G, I386F) and one helix turn above Val393 (T396G,
I397G, I397F) resulted in mutants displaying IC50 values for
UCPH-101 not significantly different fromWTGLAST (Table
2, section IV).
TM2, TM2–3 loop, TM5, and TM8
Substitutions of residues in TM2, the loop connecting TM2 and
TM3, TM5, and TM8, were found to have little or no impact on
UCPH-101-mediated inhibition of the transporter (Table 2, sec-
tion V). The only exception from this general trend was the signifi-
cant reduction inmaximal inhibition byUCPH-101 observed upon
an Ala substitution of Asp112 in GLAST, a conserved Asp residue
previously shown to be important for EAAT function (Table 2, sec-
tion V) (Ryan et al., 2004; Hotzy et al., 2012). We will refrain from
speculating about a potential involvement in this residue inUCPH-
101 binding.
The neighboring monomer
The residues in TM3, TM4c, and TM7a identified as important
for UCPH-101 activity define a crevice in each monomer in the
trimeric GLAST complex (Fig. 11). However, the distances be-
tween these residues in onemonomer and stretches of residues in
the TM2 and TM5 -helices in the neighboring monomer
Figure 9. Functional properties of UCPH-101 at GLAST mutants containing mutations of the Gly 120, Ala 123, Tyr 127, Met 251,
Phe 255, Phe 389, and Val 393 residues. Concentration–inhibition curves for UCPH-101 at WT GLAST and the GLAST mutants stably
expressed in polyclonal HEK293 cells in the [ 3H]-D-Asp uptake assay (n	 3–5).
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(Pro45-Leu57 and Ala193-Gly208 in GltPh corresponding to Phe
83-
Leu95 and Ala277-Gly292 in GLAST) are of dimensions, where
UCPH-101 could be envisioned to project out of this putative
intramonomeric pocket and form interactions with these
residues in the adjacent monomer. To investigate for this, the
residues in TM2 and TM5 were subjected to mutagenesis.
UCPH-101 did not display significantly different IC50 values at
any of the mutants containing stretches of mutations of these
residues than at the WT GLAST (Table 2, section VI).
GLT-1 mutants
Of the seven residues in TM3, TM4c, and TM7a where specific
mutations were found to impact the inhibitory potency and/or
efficacy of UCPH-101 at GLAST, only Met251 and Phe255 are not
conserved in GLT-1 (Fig. 8). To investigate whether these two
residues constitute all of the molecular determinants of the
GLAST selectivity of UCPH-101, the corresponding two residues
in GLT-1, Ile249 and Ile253, were mutated to the Met and Phe,
respectively. None of the GLT-1 mutants I249M, I253F, and
I249M/I253F displayed measurable sensitivity toward UCPH-
101 at concentrations up to 100 M (Table 2, section VII).
Construction of a homology model of
GLAST and the composition of the
proposed UCPH-101 binding site
A homology model of GLAST was con-
structed using the crystal structure of the
bacterial homolog GltPh (PDB code:
2NWX) as template (Fig. 11) (Boudker et
al., 2007). As described in the Computa-
tional chemistry section in Materials and
Methods, the Phe190-Val241 segment lo-
cated betweenTM4b andTM4c inGLAST
was not included in the model, since the
bacterial transporter does not contain a
corresponding region. Consequently, the
obtained GLAST model overlays nicely
with the GltPh structure used as a template
(data not shown). The spatial arrange-
ment of and the distances between the
seven residues found to be important for
UCPH-101 activity in the GLAST model
are given in Figure 11D. The N-terminal
part of TM3 and the TM7a align and seem
to be the key domains for putative binding
site with, whereas TM4c based on the re-
sults from the mutagenesis study may be
situated in the periphery of the binding
pocket.
In TM3, Gly120 is essential for the ac-
tivity of UCPH-101 at GLAST (Fig. 9). As
the residue composes no side chain, itmay
contribute to UCPH-101 binding via hy-
drogen bonding to the backbone amide
and/or be essential in the defining of the
size of the binding pocket. In the latter
scenario, any mutation of the residue
would be expected to decrease binding
pocket size, which seems to be consistent
with the detrimental effects of the conser-
vative G120A, G120L, and G120V muta-
tions on UCPH-101 activity (Fig. 9). The
impaired inhibitory efficacies displayed
by UCPH-101 at the Y127G, Y127L,
Y127I, and Y127R mutants and its WT-
like profile at Y127F underline the importance of an aromatic
residue in this position for UCPH-101 activity (Fig. 9). The ty-
rosine may not necessarily function as a binding partner to the
inhibitor but could be a structural component shaping the
binding pocket. Finally, judging from the WT GLAST-like
properties exhibited by UCPH-101 at the A123G and A123I
mutants, Ala 123 is unlikely to coordinate directly to UCPH-
101. However, the residue does seem to line the binding
pocket because the introduction of a bulky phenylalanine in
this position completely eliminates UCPH-101 activity at the
transporter (Fig. 9; Table 2).
The aromatic side chain of the Phe389 residue in helix 7a is
another key determinant for UCPH-101 activity at GLAST. In-
troduction of aliphatic or hydrophilic residues (Ala, Leu, Thr,
and Gln) in this position results in dramatically decreased inhib-
itor activity, and the elimination of UCPH-101 activity in F389W
could arise from the increased bulk of the aromatic side chain
(Table 2). Substitutions of Val393 situated one-helix turn above
Phe389 with the aliphatic Gly and Ile residues are well tolerated,
whereas introduction of hydrophilic or aromatic amino acids in
Figure 10. Summary of the effects of mutations of residues in the TM3 (A), TM4c (B), and TM7a (C)-helices on UCPH-101-
mediated inhibition of GLAST function. Right, IC50
mutant/IC50
WT ratios for Glu, TBOA, and UCPH-101 at the GLAST mutants.
#IC50
mutant/IC50
WT ratio: 200-fold. Left, The maximal inhibition degrees exhibited by UCPH-101 at WT and mutant GLAST
mutants (in percentages of the maximal inhibition exerted by Glu at the respective transporters) (n	 3–5). The cutoff points for
“Complete Inhibition” (90% inhibition) and “No Inhibition” (20% inhibition) defined in Table 2 are given as “CI” and “NI,”
respectively. n.d., Not determinable.
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this position clearly is not (Fig. 9). Thus, this residue is proposed
to coordinate to UCPH-101, in view of its hydrophobic nature
most likely via van der Waals interactions.
The role of Phe255 in TM4c for UCPH-101 binding is some-
what of a conundrumbecause the impairedUCPH-101 activity at
F255I is contrasted by itsWT-like properties at the F255A, F255L,
F255V, F255N, F255R, and F255W mutants (Fig. 9, Table 2).
Thus, it seems unlikely that Phe255 participates directly in
UCPH-101 binding, and instead the bulky branched side chain
introduced in F255I could be speculated to clash with the inhib-
itor by occupying a region in the binding pocket that the side
chains of the residues introduced in the other mutants do not
project into. Although the removal of the side chain of Met251 in
M251G results in a 60-fold increased IC50 value of UCPH-101,
introduction of aliphatic and aromatic side residues in this posi-
tion does not impair inhibitor activity (M251L, M251I, and
M251F) (Fig. 9; Table 2). The residue in position 251 may not be
directly involved in UCPH-101 but play a structural role for
composition of the UCPH-101 binding site. Alternatively, the im-
paired UCPH-101 activity at the M251G and F255I mutants may
arise from allosterically induced changes in the transporter domains
directly mediating the inhibitor binding, such as TM3 or TM7a.
The GLAST inhibition exerted by UCPH-101 is an
intramonomeric event
The crystal structures ofGltPh andmolecular pharmacology stud-
ies of the EAATs strongly suggest that the three monomers in the
trimeric complex function as independent functional units, also
when it comes to the substrate translocation process (Gendreau
et al., 2004; Grewer et al., 2005; Koch and Larsson, 2005; Leary et
Figure11. Homologymodelof theGLASTmonomer.A,ThetrimericGLASTcomplexviewedparallel tothemembrane(left)andfromtheextracellularsideofthemembrane(right)withthethreemonomers
given inpink, gold, and silver. In thepinkmonomer, the TM3, TM4c, andTM7a-helices arehighlighted in red, and the seven residues observed tobe important forUCPH-101activity in this studyaregivenas
stick representations in green. The localization of the substrate binding site in the pinkmonomer is indicated by the presence of L-aspartate (in purple, highlightedwith a purple circle).B, The chimera N354
monomer.AsinFigure7B, theN354domainscomposedofGLASTandGLT-1regionsaregiveningreenandred,respectively.C,TheresiduesintheGLASTmonomersubjectedtomutagenesis(thespecificmutants
are given in Table 2). Residues where none of the introduced substitutions affected UCPH-101 activity are given in yellow, whereas the seven residues where selected mutations impaired
UCPH-101 potency and/or efficacy are given as stick representations in green. D, The seven residuesdemonstrated tobe important forUCPH-101activity atGLAST. Left,Detail of thehomologymodel of the
GLASTmonomer.SpatialorientationsofTM3,TM4c,andTM7aandthesevenresidues.Right,Thedistancesbetweenthesevenresidues(CtoCdistances, inÅ).
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al., 2007; Reyes et al., 2009; Verdon and
Boudker, 2012). Accordingly, binding of
UCPH-101 to a site composed in each
monomer in the GLAST trimer could
be speculated to inhibit the transport
through the targeted monomer exclusively
and not to influence the translocation
through the two other monomers. On the
other hand, considering the close proximity
of the intramonomeric binding site of
UCPH-101 to the neighboringmonomer in
the trimer (Fig. 11), the inhibitor could also
becapableof cross-inhibition(i.e., beable to
inhibit the translocation process in one
monomer through the binding to another).
The mode of inhibition exerted by
UCPH-101 at GLAST was investigated in
two sets of experiments, where the func-
tional properties of the inhibitor were de-
termined at tsA201 cells coexpressingWT
andmutant transporters in different com-
binations (Figs. 12 and 13). In the first line
of experiments, the inhibitory properties
of UCPH-101 were determined at tsA201
cells cotransfected with cDNAs encoding
for WT GLAST and the UCPH-101-
insensitive mutant GLAST-G120L in dif-
ferent ratios (Fig. 12). The four possible
compositions of GLAST trimers assem-
bled in cells coexpressingWTGLAST and
GLAST-G120L are given in Figure 12A.
Because the Gly120 residue is located at
some distance from themonomer/mono-
mer interface in the GLAST trimer (Fig.
11A), it is reasonable to assume that the
formation of any these four trimers will
not be favored over others and that the
cDNA transfection ratio thus is the pre-
dominant determinant of the transporter
populations expressed. Judging from the
quantification of the expression of the
HA-tagged versions of the two transport-
ers in the ELISA, total and cell surface ex-
pression levels of GLAST-G120L in
tsA201 cells appear to be substantially
higher than those of WT GLAST (Fig.
12B). However, the fact that the ratios of
cell surface expressed WT and mutant
transporters thusmaynot be equivalent to
the transfection ratios used has no impact
on the conclusions from the experiment.
Glu, TBOA, and UCPH-101 exhibited
similar IC50 values at cells transfected
with the different ratios of WT GLAST
and GLAST-G120L cDNAs (Fig. 12C,
D). However, whereas Glu and TBOA
completely inhibited the [ 3H]-D-Asp
uptake in all transfected cells, a clear
correlation was observed between the
WT GLAST:GLAST-G120L transfection
ratio and the degree of inhibition ex-
erted by UCPH-101 at the respective
cells (Fig. 12C, D).
Figure 12. The GLAST inhibition exerted by UCPH-101 is an intramolecular event. A, The possible compositions of trimeric
complexes formed in tsA201 cells co-expressing WT GLAST and GLAST-G120L. B, Total and cell surface expression levels of HA-
GLAST, HA-GLAST-G120L, HA-GLAST-R497T, and HA-GLAST-G120L/R497T transiently expressed in tsA201 cells in the ELISA (n	
3).C, Concentration–inhibition curves for Glu, TBOA, andUCPH-101at tsA201 cells transfectedwithWTGLAST cDNA,GLAST-G120L
cDNA, or the two cDNAs in different ratios in the [ 3H]-D-Asp uptake assay (n	 3).D, Relationships between the transfection ratio
of WT GLAST and GLAST-G120L cDNAs and the IC50 value (left) and the maximal inhibition (right) displayed by Glu, TBOA, and
UCPH-101 in the [ 3H]-D-Asp uptake assay. IC50 values of UCPH-101 could not be determined in cells transfectedwith GLAST-G120L
cDNA or cotransfected with WT GLAST and GLAST-G120L in a 1:8 cDNA ratio.
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In the second line of experiments, we took advantage of the
knowledge from previous studies that mutations of Arg479 in
GLAST and the corresponding Arg residue in EAAC1 completely
eliminate Glu transport through the transporters (Conradt and
Stoffel, 1995; Bendahan et al., 2000). This Arg residue is con-
served throughout the EAATs, where its side chain is believed to
form an interaction with the distal carboxylate group of Glu in
the substrate binding site. In concordancewith the previous stud-
ies, no significant [3H]-D-Asp uptake could be measured in
tsA201 cells expressing the GLAST-R479T or GLAST-G120L/
R479T mutants (B. Abrahamsen and A.A. Jensen, unpublished
observations). This could not be ascribed to impaired expression
of these mutants compared with theWT transporter because cell
surface expression levels of HA-tagged GLAST-R479T and
GLAST-G120L/R479T mutants in tsA201 cells were comparable
with those of the HA-GLAST (Fig. 12B).
To investigate the effects of UCPH-101 at GLAST trimers as-
sembled from monomers with very different functionalities in
terms of substrate transport capability and UCPH-101 activ-
ity, we coexpressed all four pairwise combinations of WT
GLAST, a mutant incapable of substrate transport (GLAST-
R479T), a mutant insensitive to UCPH-101 (GLAST-G120L),
and a mutant characterized by both of these properties
(GLAST-G120L/R479T) in tsA201 cells. The possible compo-
sitions of GLAST trimers formed in each of the four combina-
tions are outlined in Figure 13A. Glu, TBOA, and UCPH-101
inhibited [ 3H]-D-Asp uptake in cells coexpressing WT GLAST
and GLAST-G120L/R479T, with IC50 values similar to those at
WT GLAST-expressing cells (Fig. 13B). In contrast, [ 3H]-D-
Asp uptake in cells coexpressing GLAST-R479T and GLAST-
G120L was not significantly inhibited by UCPH-101, whereas
Glu and TBOA displayed similar inhibitory potencies at these
cells compared with WT GLAST (Fig. 13B). As expected,
UCPH-101 displayed WT GLAST-like inhibitory potency at
cells coexpressing WT GLAST and GLAST-R479T, and it was
inactive at cells coexpressing the GLAST-G102L and GLAST-G120L/
R479Tmutants (Fig. 13B).
The Asp476 residue in GLAST, corresponding to Asp444 in
EAAC1, is another residue thought to participate in substrate
binding (Teichman and Kanner, 2007). Introduction of a D476S
mutation inGLAST eliminated the [3H]-D-Asp transport capability
of the transporter (B. Abrahamsen and A.A. Jensen, unpublished
observations). The patterns of functionalities displayed by Glu,
TBOA, and UCPH-101 at tsA201 cells coexpressing combinations
of WT GLAST, GLAST-G120L, GLAST-D476S, and GLAST-
G120L/D476S were very similar to those observed in the analo-
gous studies using R479T-containing mutants described above (B.
Abrahamsen and A.A. Jensen, unpublished observations).
In conclusion, the observations made in the experiments out-
lined in this section strongly suggest that UCPH-101 exclusively
inhibits the uptake through the GLASTmonomer that it binds to
and does not exert cross-inhibition. The very similar IC50 values
exhibited by UCPH-101 at GLAST populations formed in cells
expressing different WT:G120L monomer ratios combined with
the pronounced correlation between the transfection ratio and
the relative efficacy of the inhibitor are certainly most reconcil-
able with such a model (Fig. 12D). Moreover, the complete in-
ability of UCPH-101 to inhibit [ 3H]-D-Asp uptake in cells
coexpressing GLAST-G120L and GLAST-R479T and its effica-
cious activity at WT GLAST:GLAST-G120L/R479T-transfected
cells further substantiate the notion of an intramonomeric mode
of action, with the inhibitor having no apparent effect at the
substrate translocation through the neighboring monomers in
the trimer (Fig. 13B).
Discussion
We have recently reported the discovery of the first class of
subtype-selective inhibitors of the human EAAT1 and its rodent
Figure 13. The GLAST inhibition exerted by UCPH-101 is an intramolecular event. A, The potential GLAST trimer combinations formed in cell populations transfectedwith four different pairwise
combinations ofWTGLAST, GLAST-G120L, GLAST-R479T, and GLAST-G120L/R479T cDNAs.B, Concentration-inhibition curves for Glu, TBOA, and UCPH-101 at tsA201 cells transfectedwith different
combinations of WT GLAST, GLAST-G120L, GLAST-R479T, and GLAST-G120L/R479T cDNAs (1:1 transfection ratios) in the [ 3H]-D-Asp uptake assay (n	 4).
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ortholog GLAST (Jensen et al., 2009). In the present study, we
have investigated themechanismof action of these inhibitors and
the molecular basis for their activity at the transporter.
The functional properties of UCPH-101 and UCPH-102 at
EAAT1 in the patch-clamp recordings in this study verify the
potent inhibition of the transporter displayed by the inhibitors in
other assays (Fig. 2) (Jensen et al., 2009; Erichsen et al., 2010).
Furthermore, UCPH-101 is shown to exhibit equipotent inhibi-
tion of the substrate-activated and the uncoupled anion conduc-
tance through the transporter (Fig. 6) (Fairman et al., 1995;
Wadiche et al., 1995;Melzer et al., 2003; Ryan et al., 2004;Winter
et al., 2012). Finally, the previously reported specificity of the
inhibitors for EAAT1/GLAST over EAAT2/GLT-1 and EAAT3/
EAAC1 is demonstrated to extent to the entire EAAT family, as
UCPH-101 and UCPH-102 are inactive at EAAT4 and EAAT5 as
well (Fig. 2). These are important findings considering the
emerging roles ofUCPH-101 andUCPH-102 as pharmacological
tool compounds.
Another interesting trait of UCPH-101 is its slow binding off-
rate, which manifests itself in the long-lasting inactive state of
EAAT1 induced by even brief exposure of the transporter to the
inhibitor and in its very slow unblocking kinetics (Figs. 3C and
4A). UCPH-101 clearly does not bind irreversibly to EAAT1 be-
cause the transporter does seem able to recover from UCPH-101
exposure when subjected to a continuous wash flow (Fig. 4A).
However, the rapid clearance of the extracellular solution from
the transporter in the patch-clamp setup is not representative of
the in vivo situation. Hence, we propose that the slow unbinding
characteristics could give rise to a much more sustained inhibi-
tion of EAAT1/GLAST byUCPH-101 in vivo compared with that
induced by more reversible inhibitors. Albeit equipotent at
EAAT1/GLAST in an in vitro setting, the different unbinding
kinetics of UCPH-101 and UCPH-102 could thus translate into
different ex vivo/in vivo effects.
The differential recovery of EAAT1 function from exposure
to UCPH-101 and five of its analogs conveys an intriguing tale
about just how different binding kinetics of structurally simi-
lar ligands can be. The pronounced correlation between the
inhibitory potencies of analogs UCPH-102, UCPH-100, 1, 2
and 3 in the [ 3H]-D-Asp uptake assay and in the preincubation
experiment is in concordance with what would be expected for
reversible inhibitors with similar binding modes, and neither
the physicochemical characteristics nor the different 4- and
7-substituents of UCPH-101 seem to explain its dramatically
slower unbinding from EAAT1 (Fig. 3G; Table 1). We hypoth-
esize that the divergence arises from UCPH-101 being more
embedded in the binding site than the other analogs, and these
striking effects brought on by seemingly subtle structural
changes in the compound scaffold are currently under further
investigation in our laboratory.
In agreement with its different structure compared with sub-
strates and nonsubstrate competitive inhibitors of the EAATs
(Bunch et al., 2009), the noncompetitive inhibition of EAAT1
exerted by UCPH-101 (Figs. 5 and 6) and the WT GLAST-like
activity displayed by it at chimera N354 (Figs. 7B, C and 11B)
unequivocally identified it as an allosteric inhibitor (or negative
allosteric modulator, NAM) of EAAT1/GLAST. The observed ef-
fect of the F255I mutation on the UCPH-101-mediated inhibi-
tion of GLAST provided a handle for the subsequent delineation
of its binding site, where specific mutations of seven residues in
TM3, TM4c, and TM7a were found to impair the activity of
UCPH-101 significantly. As outlined in Results, the seven resi-
dues may not all contribute directly to UCPH-101 binding but
several observations strongly suggest that they line the binding
site for the inhibitor.Most importantly, the functional properties
displayed by Glu and TBOA at mutants containing substitutions
of these seven residues did not differ substantially from those at
WT GLAST, which demonstrates that basic transporter function
has not been compromised and that the effect of a givenmutation
thus is largely attributable to its impact on the GLAST-UCPH-
101 interaction. Second, UCPH-101 displayed WT GLAST-like
properties at numerous mutants containing mutations of other
residues in TM3, TM4c, and TM7a and at mutants with substi-
tutions in other transporter domains, which again is indicative of
specific contributions of the seven residues to UCPH-101 bind-
ing and/or close proximity to the binding site (Table 2). Finally,
the distribution patterns of Gly120, Ala123, and Tyr127 in TM3,
Met251 and Phe255 in TM4c, and Phe389 and Val393 in TM7a
imply that the three -helices present the respective residues in
the same spatial orientation, which obviously would be a prereq-
uisite for them to contribute to or line the same binding site (Fig.
11D). It is important to stress that additional GLAST residues
most likely contribute to UCPH-101 binding as well. For exam-
ple, the inactivity of UCPH-101 at GLT-1-I249M/I253F bears
witness to the fact that we clearly have not identified allmolecular
determinants in EAAT1/GLAST for the subtype selectivity of the
inhibitor.
UCPH-101 is proposed to target a predominantly hydropho-
bic crevice situated in the trimerization domain of the GLAST
monomer, and the spatial orientations and distances between the
seven identified residues in the homology model of GLAST sup-
port the notion of these lining the crevice (Fig. 11). Although the
overall size of the crevice in the model is too small to accommo-
date the UCPH-101 molecule (MOE function: Site-Finder), the
EAAT1/GLAST protein is of a flexible nature and the inhibitor
can be envisioned to wedge itself into the crevice during its bind-
ing pushing away side chains (induced fit binding mechanism).
The diverse functional consequences for the GLAST inhibi-
tion exerted by UCPH-101 arising from different mutations of
the seven key residues are interesting. The decreased inhibitory
potency or complete inactivity displayed byUCPH-101 at several
of these mutants most likely reflects varying degrees of reduced
binding affinity to the transporter. In contrast, we propose that
the partial inhibition exerted by UCPH-101 at mutants contain-
ing specific substitutions of Tyr127, Phe389, and Val393 arise from
mutation-induced changes in the binding mode of the inhibitor
and/or in the translation of this binding into effects on the sub-
strate translocation process (Figs. 9 and 10; Table 2). Here an
interesting parallel can be drawn to the metabotropic Glu recep-
tor (mGluR) field, where mutations introduced into allosteric
sites in the transmembrane domains of the receptors have been
shown to convert positive allosteric modulators (PAMs) and
“full”NAMs into partial antagonists (Malherbe et al., 2003;Mu¨h-
lemann et al., 2006; Lundstro¨m et al., 2011). In further support of
the highly modifiable efficacy of ligands acting through these
sites, several modulators exhibit dual NAM and PAM activity at
different mGluRs (Sheffler et al., 2011), and subtle structural
modifications of two series of allosteric modulators of mGluR5
have yielded everything from ago-PAMs and PAMs over full and
partial NAMs to “neutral ligands” (O’Brien et al., 2003; Rodri-
guez et al., 2005; Noetzel et al., 2012).Whether a similar degree of
functional diversity apply for ligands targeting the UCPH-101
binding site in EAAT1/GLAST depends on the inherent nature of
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the coupling between the allosteric site and the substrate translo-
cation process as well as on the specific ligand. In structure–
activity relationship studies of this compound scaffold, we have
not identified partial inhibitors or PAMs of EAAT1, and none of
the analogs developed so far have exhibited activity at EAAT2 or
EAAT3 (Jensen et al., 2009; Erichsen et al., 2010; Huynh et al.,
2012a; b). However, that does not rule out the possibility that
future UCPH-101 analogs or other ligands targeting this site
could exhibit functionalities other than full NAM activity at
EAAT1 and even possess activities at other EAAT subtypes.
In conclusion, this study represents one the most elaborate
explorations of the molecular basis for an allosteric modulator of
a neurotransmitter transporter reported to date (Vandenberg et
al., 2004; Kristensen et al., 2011). The mechanism of action of
UCPH-101 and its analogs underlines the functional importance
of the trimerization domain of the EAAT. Whatever molecular
constraint binding of this inhibitor class to EAAT1/GLAST intro-
duces in the transporter protein this domain is clearly more than
a rigid hinge enabling the dramatic movements of the transport
domain during substrate translocation (Boudker and Verdon,
2010; Jiang andAmara, 2011). Equally interesting is the feasibility
of modulating EAAT function by ligands targeting regions other
than its transport domain. Because of the conserved nature of the
substrate binding sites in the five EAATs, precious few subtype-
selective orthosteric ligands have been identified to date (Bunch
et al., 2009). Another inherent flaw of the orthosteric ligand, be it
a substrate or an inhibitor, is that it inevitably will inhibit Glu
uptake through the EAAT, which limits the therapeutic potential
in these ligands to disorders characterized by glutamatergic hy-
pofunction (Field et al., 2011) or by reversal of EAAT function
(Rossi et al., 2000). For a ligand to augment the Glu transport
capacity of the EAAT, it would have to act through an allosteric
site in the transporter. In this regard, the UCPH-101 binding site
and other allosteric sites in the EAAT trimer constitute putative
hot spots for novel ligands characterized by unique subtype se-
lectivity and functional characteristics at the transporters.
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